Tivic Health Systems, Inc. (TIVC)
$
2.69
-0.11 (-4.09%)
Key metrics
Financial statements
Free cash flow per share
-6.2499
Market cap
3.1 Million
Price to sales ratio
6.7762
Debt to equity
0
Current ratio
2.2436
Income quality
0.8655
Average inventory
294.5 Thousand
ROE
-2.0976
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Tivic Health Systems Inc. operates as a bioelectronic device company, specializing in non-invasive neuromodulation products aimed at treating inflammatory conditions. Its flagship product, ClearUP, is a medical device designed to alleviate sinus and nasal inflammation, which positions the company as an innovative contributor to healthcare solutions. The earnings per share (EPS) is reported at -$19.67 indicating the company's profitability on a per-share basis. Moreover, the net total of other income and expenses is $6,000.00 reflecting non-core financial activities that may influence its financial health. The overall costs and expenses for the company stand at $6,441,000.00 showcasing its total spending, while operating expenses amount to $5,663,000.00 encompassing a range of operational costs incurred during its activities. The operating income ratio is -7.26 providing insight into the company's operational profitability margin, which is crucial for evaluating its financial effectiveness in the market. As a small-cap player with a market capitalization of $2,913,961.00 Tivic Health is considered a notable entity within the industry landscape. The stock is affordable at $3.07 making it suitable for budget-conscious investors seeking to engage with the market. The stock also has a high average trading volume of 1,024,584.00 indicating strong liquidity, which is essential for investors looking to buy or sell shares without significant price fluctuations. It is a key player in the Medical - Devices industry, contributing significantly to the overall market landscape and fostering advancements that may benefit consumers. Additionally, it belongs to the Healthcare sector, driving innovation and growth, which underscores its potential impact on the healthcare ecosystem. Through strategic initiatives and consumer outreach via platforms like Amazon.com and Walmart.com, Tivic Health Systems, Inc. continues to expand its market presence and cater to the demands of its customer base.
Is Tivic Health Systems, Inc. (TIVC) a good investment?
Investing in Tivic Health Systems, Inc. (TIVC) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is Tivic Health Systems, Inc. (TIVC)'s stock forecast?
Analysts predict Tivic Health Systems, Inc. stock to fluctuate between $2.43 (low) and $15.64 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Tivic Health Systems, Inc.'s market capitalization?
As of 2025-10-28, Tivic Health Systems, Inc.'s market cap is $2,913,961, based on 1,083,257 outstanding shares.
How does Tivic Health Systems, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Tivic Health Systems, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Tivic Health Systems, Inc. (TIVC) stock?
To buy Tivic Health Systems, Inc. (TIVC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for TIVC. Place an order (Market, Limit, etc.).
What is the best time to invest in Tivic Health Systems, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Tivic Health Systems, Inc. stock ever split?
Tivic Health Systems, Inc.'s last stock split was 1:17 on 2025-03-07.
How did Tivic Health Systems, Inc. perform in the last earnings report?
Revenue: $780,000 | EPS: -$19.67 | Growth: -88.87%.
Where can I find Tivic Health Systems, Inc.'s investor relations reports?
Visit https://www.tivichealth.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Tivic Health Systems, Inc.?
You can explore historical data from here
What is the all-time high and low for Tivic Health Systems, Inc. stock?
All-time high: $11,050 (2021-11-11) | All-time low: $2.43 (2025-04-01).
What are the key trends affecting Tivic Health Systems, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that CEO, Jennifer Ernst, will participate in the eighth annual Constellation Forum, a global conversation on Bioelectronic Medicine. She will join other leaders in the field to discuss the opportunities for advancing bioelectronic medicine. When: Thursday, Oct. 23, at 11:55 a.m. ET/8:55 a.m. PT Panel Title: Building a Big Tent Bioelectronic Medicine stands to.
businesswire.com
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that the company's CEO will present during the Emerging Growth virtual conference set to take place on September 24 & 25, 2025. WHO: Jennifer Ernst, Chief Executive Officer WHERE: September 25, 2025 WHEN: 11:25AM - 11:55AM Eastern Time Jennifer Ernst, CEO of Tivic, will deliver a formal presentation detailing the company's strategic transformation into the.
businesswire.com
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that it has completed verification of its Entolimod™ cell line, the first step in establishing Current Good Manufacturing Practices (CGMP) in preparation for a Biologics License Application, or BLA. Cell line verification in recombinant protein production is required because it ensures the processes used to grow cells and activate protein expression do not comp.
businesswire.com
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced it has received, from Statera Biopharma, two investigational new drug applications (INDs) for its lead candidate, Entolimod™. The two INDs cover the use of Entolimod to treat acute radiation syndrome, including both hematopoietic (ARS-H) and gastrointestinal (ARS-GI) sub-syndromes, and the use of Entolimod to treat advanced cancers, including as an anti-tumor a.
businesswire.com
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, is proud to announce it advanced discussions with key US Government agencies through its participation in the 2025 Military Health System Research Symposium (MHSRS), held August 4-7, 2025, in Kissimmee, Florida. The MHSRS is the Department of Defense's premier scientific meeting that brings together military, academic, and industry experts to discuss medical research and innovation.
seekingalpha.com
Tivic Health Systems, Inc. (NASDAQ:TIVC ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Jennifer Ernst - Co-Founder, CEO & Director Lisa G. Wolf - CFO and Principal Financial & Principal Accounting Officer Operator Welcome to Tivic Health Systems Second Quarter 2025 Financial Results and Operational Update Conference Call.
businesswire.com
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that key proposals needed to carry out the company's strategic transformation were approved by shareholders at its annual meeting held on June 30, 2025. The approved proposals included the issuance of equity as a form of payment pursuant to Tivic's worldwide exclusive license agreement for Entolimod™ and Entolasta™, including for uses in acute radiation syndrom.
businesswire.com
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company developing treatments that stimulate immune pathways to treat disease, today announced it has completed all study visits in the Optimization Study for its patent pending, non-invasive cervical vagus nerve stimulation (ncVNS) device. Initial findings reinforce the importance of personalization for therapeutic efficacy. Tivic expects to release the study results later this year.
businesswire.com
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today its Virtual Annual General Meeting of Shareholders will be held on Monday, June 30, 2025 at 1:00 PM, Pacific Time | 4:00 PM Eastern Time. The Company has adopted a virtual format for its Annual Meeting to provide a consistent and convenient experience for all stockholders regardless of their location. In lieu of a live Q&A session, stockholders can submit questio.
See all news
